Interaction of Bay t 3839 coprecipitates with insoluble excipients
Identifieur interne : 000A98 ( Main/Exploration ); précédent : 000A97; suivant : 000A99Interaction of Bay t 3839 coprecipitates with insoluble excipients
Auteurs : Andreas Ohm [Allemagne]Source :
- European Journal of Pharmaceutics and Biopharmaceutics [ 0939-6411 ] ; 1999.
English descriptors
- KwdEn :
Abstract
Bay t 3839 is an extremely sparingly soluble drug and results in severe problems with regard to oral bioavailability. In order to improve the dissolution performance a coprecipitate formulation approach was investigated and the necessary ratio polyvinylpyrrolidone (pvp) to drug substance was found to be approximately 15 in order to achieve a sufficient supersaturation in 900 ml 0.1 N HCl, which is considered to be an appropriate as well as challenging in vitro test method. Surprisingly substantial differences in the dissolution characteristics of coprecipitate granulates were revealed when the coprecipitate was formed on excipients which was not the case when pure pvp/drug coprecipitates were submitted to dissolution testing. As substantial deterioration of the supersaturation capability was detected only in the case of insoluble excipients it is concluded that solid/liquid interfaces during the dissolution step act as recrystallization inducers. In case of soluble fillers/adsorbents, like mannitol, the supersaturation capability could be maintained also after the granulation step. Therefore, it is likely that in the case of extremely challenging drug candidates like, e.g. Bay t 3839, the supersaturated solution is less stable than in the case of more soluble compounds. These more susceptible coprecipitates can be stabilized by proper selection of the granulation excipients. Additionally the admixture of crystallization inhibiting agents like sodium dodecyl sulfate (SDS) offers the opportunity to decrease the necessary ratio pvp/Bay t 3839 considerably (to a ratio of ∽7).
Url:
DOI: 10.1016/S0939-6411(99)00080-6
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Interaction of Bay t 3839 coprecipitates with insoluble excipients</title><author><name sortKey="Ohm, Andreas" sort="Ohm, Andreas" uniqKey="Ohm A" first="Andreas" last="Ohm">Andreas Ohm</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E0F851C05BF75633199E4C12C3290F58DF78366A</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1016/S0939-6411(99)00080-6</idno><idno type="url">https://api.istex.fr/document/E0F851C05BF75633199E4C12C3290F58DF78366A/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000821</idno><idno type="wicri:Area/Main/Curation">000816</idno><idno type="wicri:Area/Main/Exploration">000A98</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Exploration">000A98</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Interaction of Bay t 3839 coprecipitates with insoluble excipients</title><author><name sortKey="Ohm, Andreas" sort="Ohm, Andreas" uniqKey="Ohm A" first="Andreas" last="Ohm">Andreas Ohm</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Pharmaceutical Technology 2, Bayer AG, Leverkusen</wicri:regionArea><wicri:noRegion>Leverkusen</wicri:noRegion><wicri:noRegion>Leverkusen</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Allemagne</country></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Pharmaceutics and Biopharmaceutics</title><title level="j" type="abbrev">EJPB</title><idno type="ISSN">0939-6411</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1999">1999</date><biblScope unit="volume">49</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="183">183</biblScope><biblScope unit="page" to="189">189</biblScope></imprint><idno type="ISSN">0939-6411</idno></series><idno type="istex">E0F851C05BF75633199E4C12C3290F58DF78366A</idno><idno type="DOI">10.1016/S0939-6411(99)00080-6</idno><idno type="PII">S0939-6411(99)00080-6</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0939-6411</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Coprecipitate</term><term>Polyvinylpyrrolidone</term><term>Recrystallization of supersaturated solutions</term><term>Solubility of filler material</term><term>Sparingly soluble drug substance</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Bay t 3839 is an extremely sparingly soluble drug and results in severe problems with regard to oral bioavailability. In order to improve the dissolution performance a coprecipitate formulation approach was investigated and the necessary ratio polyvinylpyrrolidone (pvp) to drug substance was found to be approximately 15 in order to achieve a sufficient supersaturation in 900 ml 0.1 N HCl, which is considered to be an appropriate as well as challenging in vitro test method. Surprisingly substantial differences in the dissolution characteristics of coprecipitate granulates were revealed when the coprecipitate was formed on excipients which was not the case when pure pvp/drug coprecipitates were submitted to dissolution testing. As substantial deterioration of the supersaturation capability was detected only in the case of insoluble excipients it is concluded that solid/liquid interfaces during the dissolution step act as recrystallization inducers. In case of soluble fillers/adsorbents, like mannitol, the supersaturation capability could be maintained also after the granulation step. Therefore, it is likely that in the case of extremely challenging drug candidates like, e.g. Bay t 3839, the supersaturated solution is less stable than in the case of more soluble compounds. These more susceptible coprecipitates can be stabilized by proper selection of the granulation excipients. Additionally the admixture of crystallization inhibiting agents like sodium dodecyl sulfate (SDS) offers the opportunity to decrease the necessary ratio pvp/Bay t 3839 considerably (to a ratio of ∽7).</div></front></TEI><affiliations><list><country><li>Allemagne</li></country></list><tree><country name="Allemagne"><noRegion><name sortKey="Ohm, Andreas" sort="Ohm, Andreas" uniqKey="Ohm A" first="Andreas" last="Ohm">Andreas Ohm</name></noRegion><name sortKey="Ohm, Andreas" sort="Ohm, Andreas" uniqKey="Ohm A" first="Andreas" last="Ohm">Andreas Ohm</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/SchutzV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A98 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A98 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Musique
|area= SchutzV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:E0F851C05BF75633199E4C12C3290F58DF78366A
|texte= Interaction of Bay t 3839 coprecipitates with insoluble excipients
}}
| This area was generated with Dilib version V0.6.38. |  |